CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure

Stock News08-07 10:52

CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.

On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.

Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on CARSGEN-B's proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163799508?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163799508","market":"sg","top_or_hot":-1,"title":"CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure","media":"Stock News","content":"<p><b>CARSGEN-B</b> (<b>02171</b>) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.<br><br>On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.<br><br>Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on <b>CARSGEN-B</b>'s proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-07 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CARSGEN-B</b> (<b>02171</b>) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.<br><br>On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.<br><br>Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on <b>CARSGEN-B</b>'s proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1163799508","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163799508","pubTimestamp":1786071162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.On...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B","BK4588":"碎股","KCAI":"KraneShares China Alpha Index ETF","BK1587":"次新股","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","BK1585":"昨日强势股"},"translate_title":"CARSGEN-B (02171) 飙升超过 4%，CT1190B 在二线失败后获得 IND Nod 用于 R/R LBCL 患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"KCAI":1,"02171":1},"content_text":"CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on CARSGEN-B's proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163799508","isCrawlerRequest":true}